stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Shares outstanding
Travere Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $89.2M, up 13.1% from $78.9M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $94.6M. Over the past ten years it has ranged from $37.6M (fiscal 2015) to $89.2M (fiscal 2025) — the current reading is the highest in ten years. Travere Therapeutics, Inc. ranks 160th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $89.2M | 13.09% |
| FY2024 | $78.9M | 6.22% |
| FY2023 | $74.3M | 16.48% |
| FY2022 | $63.8M | 6.56% |
| FY2021 | $59.8M | 25.86% |
| FY2020 | $47.5M | 12.28% |
| FY2019 | $42.3M | 4.72% |
| FY2018 | $40.4M | 4.29% |
| FY2017 | $38.8M | 1.26% |
| FY2016 | $38.3M | 1.88% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $94.6M | 1.23% |
| Jun 2026 | $93.5M | 1.75% |
| Mar 2026 | $91.9M | 2.98% |
| Dec 2025 | $89.2M | (13.06%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ERAS Erasca, Inc. compare | $311.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $193.8M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| EWTX Edgewise Therapeutics, Inc. compare | $120.9M |
| DFTX Definium Therapeutics, Inc. compare | $110.7M |
| CRSP CRISPR Therapeutics AG compare | $96.7M |
| TVTX Travere Therapeutics, Inc. | $94.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $57.3M |
| MANE Veradermics Incorporated compare | $40.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement